2-[(3,4-dimethylphenyl)oxy]-N-[(1R)-2-(4-methylpiperazin-1-yl)-2-oxo-1-{[(phenylmethyl)oxy]methyl}ethyl]pyridine-3-carboxamide | 1239354-21-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[(3,4-dimethylphenyl)oxy]-N-[(1R)-2-(4-methylpiperazin-1-yl)-2-oxo-1-{[(phenylmethyl)oxy]methyl}ethyl]pyridine-3-carboxamide
• 英文别名: 2-(3,4-dimethylphenoxy)-N-[(2R)-1-(4-methylpiperazin-1-yl)-1-oxo-3-phenylmethoxypropan-2-yl]pyridine-3-carboxamide
• CAS: 1239354-21-2
• 化学式: C₂₉H₃₄N₄O₄
• 分子量: 502.613
• InChiKey: HRTMPRUBSSPKAJ-AREMUKBSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  84
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3,4-二甲基苯酚 在 水 、 caesium carbonate 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 lithium hydroxide 作用下， 以 四氢呋喃 、 N,N-二甲基乙酰胺 、 乙腈 为溶剂， 反应 58.0h， 生成 2-[(3,4-dimethylphenyl)oxy]-N-[(1R)-2-(4-methylpiperazin-1-yl)-2-oxo-1-{[(phenylmethyl)oxy]methyl}ethyl]pyridine-3-carboxamide
  参考文献：
  名称：

  Discovery of a new class of glucosylceramide synthase inhibitors

  摘要：

  A novel series of potent inhibitors of glucosylceramide synthase are described. The optimization of biochemical and cellular potency as well as ADME properties led to compound 23c. Broad tissue distribution was obtained following oral administration to mice. Thus 23c could be another useful tool compound for studying the effects of GCS inhibition in vitro and in vivo. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.037

文献信息

• Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases
  申请人：ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE)

  公开号：US11065238B2

  公开（公告）日：2021-07-20

  The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.

  本发明涉及用于治疗运动神经元疾病，特别是遗传性痉挛性截瘫的神经节苷脂代谢抑制剂。
• INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES
  申请人：ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE)

  公开号：US20190350913A1

  公开（公告）日：2019-11-21

  The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.
• [EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE
  申请人：EXELIXIS INC

  公开号：WO2010091104A1

  公开（公告）日：2010-08-12

  The present invention comprises glucosylceramide synthase (GCS) inhibitors of structural formula (I), and pharmaceutically acceptable salts thereof, wherein R1, E, A, L, X1, Q, R4, R5, m and n, are as defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which GCS is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which GCS is a mediator or is implicated.